Yunnan-based KPC Pharmaceuticals Inc. (SHA: 600422) has announced that its dihydroartemisinin/piperaquine 40mg/320mg formulation has received Prequalification (PQ) status from the World Health Organization (WHO). This critical milestone allows the anti-malaria drug to be included in the procurement scope of international organizations and public health institutions, enhancing its accessibility in malaria-affected regions.
Global Malaria Landscape: The Need for Effective Treatments
According to WHO statistics, there were approximately 247 million cases of malaria and 625,000 deaths worldwide in 2021. Artemisinin-based combination therapy remains the most effective treatment for severe malaria, underscoring the importance of drug availability. In that same year, global distribution of artemisinin-based medications reached 242 million through international public procurement bids. KPC’s dihydroartemisinin/piperaquine is one of only three such products worldwide to achieve PQ status.
KPC Pharma’s Expanding Market Reach
KPC Pharmaceuticals has developed a robust international sales network for its artemisinin products, extending to over 50 countries. The dihydroartemisinin/piperaquine drug is registered in 24 countries and has generated notable sales figures, totaling RMB 23.66 million (approximately USD 3.3 million) in 2022. The achievement of PQ status positions KPC Pharma to further expand its market presence in the global fight against malaria.-Fineline Info & Tech
